Initial findings from a Phase 3 efficacy trial suggest Ionis Pharmaceuticals’ RNA-targeted treatment, given monthly or bimonthly, cut angioedema attacks more than placebo, the firm said Monday. The ...
Shares of Pharvaris PHVS rose nearly 22% on Wednesday after the company announced positive results from the phase III RAPIDe-3 study evaluating its lead pipeline drug deucrictibant in the hereditary ...
KalVista Pharmaceuticals, Inc. (KALV) had achieved a huge win announced just the other day on July 7th of 2025, whereby the FDA had approved its oral on-demand Hereditary Angioedema [HAE] plasma ...
Hereditary angioedema (HAE) is a rare genetic disorder that causes episodes of severe swelling throughout your body. It is caused by abnormal immune responses. But unlike allergic swelling, HAE is not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results